<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-444" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dysplastic Nevi</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baigrie</surname>
            <given-names>Dana</given-names>
          </name>
          <aff>Campbell University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tanner</surname>
            <given-names>Laura S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dana Baigrie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Laura Tanner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-444.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A dysplastic nevus is also referred to as an atypical or Clarks nevus and has been the topic of much debate in dermatology and dermatopathology. It is an acquired mole demonstrating a unique clinical and histopathologic appearance that sets it apart from the common nevus. These moles appear atypical clinically, often with a fried-egg appearance, and are commonly biopsied by providers due to the concern for melanoma. This activity reviews the cause and pathophysiology of dysplastic nevus and highlights the interprofessional team's role in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of dysplastic nevi.</p></list-item><list-item><p>Interpret&#x000a0;the presentation of dysplastic nevi.</p></list-item><list-item><p>Differentiate&#x000a0;the management options available for dysplastic nevi.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and outcomes in patients with dysplastic nevi.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=444&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=444">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-444.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A dysplastic nevus is also referred to as an atypical or Clark nevus and has been the topic of much debate in dermatology and dermatopathology. It is an acquired mole demonstrating a unique clinical and histopathologic appearance that sets it apart from the common nevus. These moles appear atypical clinically, often with a &#x0201c;fried-egg&#x0201d; appearance, and are commonly biopsied by providers due to the concern for melanoma. A clinical diagnosis of atypical nevi is based upon the presence of at least&#x000a0;3 of the following features: diameter greater than 5 mm, ill-defined borders, irregular margins, and lesional color variation. Individuals with these nevi have an increased risk for melanoma, but contrary to some individual beliefs, these are&#x000a0;considered banal nevi.<xref ref-type="bibr" rid="article-444.r1">[1]</xref><xref ref-type="bibr" rid="article-444.r2">[2]</xref><xref ref-type="bibr" rid="article-444.r3">[3]</xref></p>
      </sec>
      <sec id="article-444.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of dysplastic nevi is not entirely clear. The phenotypic expression of dysplastic nevi has been determined to be related to environmental and genetic factors. Factors such as sun sensitivity, fair skin tone, light eye and hair color, and freckling propensity are inherited traits that strongly predict the development of nevi. Also,&#x000a0;ultraviolet (UV) sunlight exposure has been shown to accentuate the expression of the dysplastic nevi phenotype. A higher incidence of the dysplastic nevus syndrome phenotype has been demonstrated in epidemiologic studies in children with a history of greater exposure to UV light.<xref ref-type="bibr" rid="article-444.r4">[4]</xref><xref ref-type="bibr" rid="article-444.r5">[5]</xref><xref ref-type="bibr" rid="article-444.r6">[6]</xref></p>
        <p>A sequential progression model for dysplastic nevi as the intermediate between banal nevi and melanoma has been proposed in the past by Clark and is still a supported model by many dermatologists. However, this model suggests that mutations in the nevi would be shared with melanoma, which has not been demonstrated in the literature. Also, approximately 25% of melanomas are estimated to arise in pre-existing nevi, and 75% arise de novo. One study demonstrated the risk of a dysplastic nevus evolving into melanoma is 0.0005% for people younger than 40 years. Dysplastic nevi tend to be stable over time.&#x000a0;</p>
      </sec>
      <sec id="article-444.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Dysplastic nevi may exist in approximately 2% to 18% of the population. Individuals with these nevi are at increased risk for melanoma. In&#x000a0;White race individuals in the United States, the lifetime risk of developing melanoma is less than 1%, whereas, in patients with dysplastic nevi, the risk is greater than 10%. The risk of melanoma increases significantly to 50% in individuals with a family history of dysplastic nevus syndrome. Dysplastic nevi are relatively uncommon in the Japanese population. The incidence of dysplastic nevi in the pediatric population is very low.</p>
      </sec>
      <sec id="article-444.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of dysplastic nevi is not well understood. The inheritance pattern is complicated, as it occurs more commonly than autosomal dominant inheritance. Unlike patients with familial melanoma, who often demonstrate a <italic toggle="yes">CDKN2A</italic> gene mutation, dysplastic nevi do not commonly display this mutated gene. Recent studies noted that dysplastic nevi are clonal like common nevi, and some have BRAF, p16, or p53 alterations in expression. Also, dysplastic nevi were found to have higher proliferative rates than common nevi, as measured by proliferative markers Ki-67 and cyclin D1.<xref ref-type="bibr" rid="article-444.r7">[7]</xref><xref ref-type="bibr" rid="article-444.r8">[8]</xref><xref ref-type="bibr" rid="article-444.r9">[9]</xref></p>
      </sec>
      <sec id="article-444.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologically, dysplastic nevi have 4 characteristic features that help distinguish them from other nevi or melanoma. These features include intraepidermal lentiginous hyperplasia of melanocytes, cytological atypia of melanocytes, lamellar and concentric fibroplasia (stromal response), and architectural atypia. Compound dysplastic nevi often have a &#x0201c;shoulder sign&#x0201d; in which the epidermal component extends beyond or &#x0201c;shoulders&#x0201d; the dermal component.<xref ref-type="bibr" rid="article-444.r10">[10]</xref></p>
        <p>The cytological atypia is random and includes enlarged dark nuclei with large nucleoli. This atypia is often graded from mild to severe. However, this is subjective, based on the dermatopathologist reading the slides. Cytological atypia is not exclusive to dysplastic nevi and may be seen in any nevus. Many studies have examined inter- and intra-observer concordance between dermatopathologists in diagnosing dysplastic nevi concerning cytological atypia grading. The results have been mixed and may vary widely from&#x000a0;1 dermatopathologist to another, but it is speculated that an individual dermatopathologist&#x02019;s grading likely remains constant.<xref ref-type="bibr" rid="article-444.r10">[10]</xref></p>
      </sec>
      <sec id="article-444.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Dysplastic nevi tend to be larger than the ordinary nevi, measuring approximately greater than 5 mm in diameter. They often contain multiple colors, including light brown, dark brown, and pink. They often appear as a &#x0201c;fried egg&#x0201d; with a darker papular central lesion and surrounding macular lighter shade. This clinical appearance is atypical, and they often follow the ABCDE guidelines for melanoma, including asymmetry, border irregularity, color variation, diameter (greater than 6 mm), and evolving lesion. Most of these atypically-appearing nevi are biopsied as they are a cause&#x000a0;of concern for atypical moles or melanoma.<xref ref-type="bibr" rid="article-444.r6">[6]</xref>&#x000a0;Dysplastic nevus syndrome involves patients with 50 or more dysplastic nevi. These patients develop atypical nevi in adolescence and adulthood. A patient is said to have dysplastic nevus syndrome if they have&#x000a0;5 or more atypical melanocytic nevi. A variant of dysplastic nevus described in the early 1990s is known as the lentiginous dysplastic nevus of the elderly. Some regard this as nevoid lentigo maligna or evolving or early melanoma in situ of the elderly. These nevi appear in elderly individuals older than 60 and tend to arise on the back in males and the legs in females. Rarely, dysplastic nevi can present in an eruptive form, primarily seen in immunosuppressed patients.</p>
      </sec>
      <sec id="article-444.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A lesion suspicious clinically for dysplastic nevus should be excised completely, whether by shave, punch, or excisional biopsy. The complete removal of the lesion is so the dermatopathologist may evaluate the entire lesion for symmetry and appreciate the shoulder sign, characteristic of dysplastic nevi. For this reason, an incisional biopsy is not recommended.<xref ref-type="bibr" rid="article-444.r11">[11]</xref><xref ref-type="bibr" rid="article-444.r12">[12]</xref>&#x000a0;Dermoscopy is a tool dermatologists use to evaluate pigment patterns and secondary features, such as vascularity in suspicious skin lesions. Clear and well-studied dermoscopic features are characteristic of certain neoplasms, such as basal cell carcinoma, seborrheic keratosis, and melanoma. However, no dermoscopic criteria currently distinguish dysplastic nevi from melanoma in situ.<xref ref-type="bibr" rid="article-444.r13">[13]</xref></p>
      </sec>
      <sec id="article-444.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of dysplastic nevi is controversial and varies from provider to provider. A survey of physicians in the American Academy of Dermatology organization reported that approximately two-thirds of the respondents prefer to re-excise dysplastic nevi if margins are reported to be positive in the initial biopsy. The reasoning for this could be if the incompletely excised nevus grew back in the biopsy scar, it may clinically and histologically be indistinguishable from melanoma. This is referred to as the &#x0201c;pseudo-melanoma&#x0201d; phenomenon.&#x000a0;</p>
        <p>Many authors agree that most dysplastic nevi do not need to be re-excised after the initial biopsy. An extensive review concluded that dysplastic nevi are &#x0201c;fundamentally variants of common nevi.&#x0201d; However, if a provider worries about how a lesion appears clinically, this should trump what is reported histopathologically, and the lesion should be completely excised. It is also agreed upon that a dysplastic nevus with severe atypia or&#x000a0;1 that cannot be distinguished histologically from melanoma should be re-excised with appropriate margins (typically at least 5 mm margins).<xref ref-type="bibr" rid="article-444.r13">[13]</xref>&#x000a0;Patients with a history of dysplastic nevi are recommended to wear sun protection.<xref ref-type="bibr" rid="article-444.r13">[13]</xref></p>
      </sec>
      <sec id="article-444.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for dysplastic nevi includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Blue nevi</p>
          </list-item>
          <list-item>
            <p>Basal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Cutaneous melanoma</p>
          </list-item>
          <list-item>
            <p>Dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Lentigo</p>
          </list-item>
          <list-item>
            <p>Melanocytic nevi</p>
          </list-item>
          <list-item>
            <p>Spitz nevus</p>
          </list-item>
          <list-item>
            <p>Seborrheic keratosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-444.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients&#x000a0;with&#x000a0;dysplastic nevi&#x000a0;is excellent. However,&#x000a0;those with a history of&#x000a0;dysplastic nevi&#x000a0;have an&#x000a0;increased risk of developing melanoma. Therefore, recommendations&#x000a0;are for regular skin check-ups with a dermatologist.&#x000a0;Management of mildly dysplastic nevi can entail nothing more than regular observation. However, severely dysplastic nevi require surgical removal. Based on the degree of clinical abnormality, moderately atypical nevi can&#x000a0;be managed with close observation if there are many or surgical removal if there are only a few.<xref ref-type="bibr" rid="article-444.r14">[14]</xref><xref ref-type="bibr" rid="article-444.r4">[4]</xref></p>
      </sec>
      <sec id="article-444.s12" sec-type="Complications">
        <title>Complications</title>
        <p>As with any mole, patients need to be vigilant for the potential development of melanoma. Both patients and their healthcare providers must be alert for changes in the dysplastic nevi. A severely dysplastic nevus is indistinguishable from early melanoma.&#x000a0;</p>
      </sec>
      <sec id="article-444.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients need to be counseled to avoid&#x000a0;UV light, including from the sun and tanning beds. When outdoors in the sun, they should use sunscreen and cover their exposed skin as much as is practical with long sleeves, broad-brimmed hats, and other protective garments.</p>
      </sec>
      <sec id="article-444.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A dermatologist primarily manages dysplastic nevi. However, most patients present with an abnormal skin lesion to their primary care provider. It is important for these healthcare workers to consult with a dermatologist first when they suspect a dysplastic nevus. A lesion suspicious clinically for dysplastic nevus should be excised completely, whether by shave, punch, or excisional biopsy. The complete removal of the lesion is so the dermatopathologist may evaluate the entire lesion for symmetry and appreciate the shoulder sign, characteristic of dysplastic nevi. For this reason, an incisional biopsy is not recommended. Dermoscopy is a tool dermatologists use to evaluate pigment patterns and secondary features, such as vascularity in suspicious skin lesions. There are clear and well-studied dermoscopic features characteristic&#x000a0;of&#x000a0;certain neoplasms, such as basal cell carcinoma, seborrheic keratosis, and melanoma. However, no dermoscopic criteria currently distinguish dysplastic nevi from melanoma in situ.</p>
      </sec>
      <sec id="article-444.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=444&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=444">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/dysplastic-nevi-atypical-mole/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=444">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/444/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=444">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-444.s16">
        <title>References</title>
        <ref id="article-444.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strazzulla</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okhovat</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic, misdiagnosis, and survival differences between clinically amelanotic melanomas and pigmented melanomas.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>1292</fpage>
            <page-range>1292-1298</page-range>
            <pub-id pub-id-type="pmid">30654075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Unamuno Bustos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sahuquillo Torralba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moles Poveda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Sim&#x000f3;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simarro Farinos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Llavador Ros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palanca Suela</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Botella Estrada</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Telomerase Expression in a Series of Melanocytic Neoplasms.</article-title>
            <source>Actas Dermosifiliogr (Engl Ed)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>110</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-219</page-range>
            <pub-id pub-id-type="pmid">30591199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siiskonen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sironen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tyynel&#x000e4;-Korhonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirschovits-Gerz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Valkonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auvinen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pasonen-Sepp&#x000e4;nen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.</article-title>
            <source>Melanoma Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-247</page-range>
            <pub-id pub-id-type="pmid">30399061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bsirini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Histologic mimics of malignant melanoma.</article-title>
            <source>Singapore Med J</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>602</fpage>
            <page-range>602-607</page-range>
            <pub-id pub-id-type="pmid">29774360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colebatch</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Trajectories of premalignancy during the journey from melanocyte to melanoma.</article-title>
            <source>Pathology</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-23</page-range>
            <pub-id pub-id-type="pmid">29132722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Strazzulla</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Association of clinicopathological features of melanoma with total naevus count and a history of dysplastic naevi: a cross-sectional retrospective study within an academic centre.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-572</page-range>
            <pub-id pub-id-type="pmid">29450912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winkelmann</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Farberg</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Glazer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cockerell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sober</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Leachman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>High</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pariser</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Integrating Skin Cancer-Related Technologies into Clinical Practice.</article-title>
            <source>Dermatol Clin</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>565</fpage>
            <page-range>565-576</page-range>
            <pub-id pub-id-type="pmid">28886814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madigan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Treyger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kohen</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Compliance with serial dermoscopic monitoring: An academic perspective.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1171</fpage>
            <page-range>1171-1175</page-range>
            <pub-id pub-id-type="pmid">27665211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghavan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of genitourinary malignancy.</article-title>
            <source>Semin Oncol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-52</page-range>
            <pub-id pub-id-type="pmid">27178687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valdebran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bandino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elbendary</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arudra</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>de Feraudy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Nuclear and cytoplasmic features in the diagnosis of Clark's nevi.</article-title>
            <source>J Cutan Pathol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>204</fpage>
            <page-range>204-207</page-range>
            <pub-id pub-id-type="pmid">29193203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendahl</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Grant-Kels</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Que</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Dysplastic nevus: Fact and fiction.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>507</fpage>
            <page-range>507-12</page-range>
            <pub-id pub-id-type="pmid">26037217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Atypical moles: diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2015</year>
            <month>Jun</month>
            <day>01</day>
            <volume>91</volume>
            <issue>11</issue>
            <fpage>762</fpage>
            <page-range>762-7</page-range>
            <pub-id pub-id-type="pmid">26034853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winkelmann</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Management of dysplastic nevi: A 14-year follow-up survey assessing practice trends among US dermatologists.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>1056</fpage>
            <page-range>1056-9</page-range>
            <pub-id pub-id-type="pmid">26568339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-444.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Shaub</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Swetter</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of surgical re-excision versus observation of severely dysplastic nevi: A single-institution, retrospective cohort study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>238</fpage>
            <page-range>238-240</page-range>
            <pub-id pub-id-type="pmid">31325549</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
